Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Inclusion Criteria: * Male or female subject aged ≥ 18 years. * Advanced-stage (overall stage III and IV) head and neck cancers (sinonasal oral cavity, oropharynx, larynx, and hypopharynx) undergoing surgical resection and then adjuvant radiation. Primary and recurrence cases are acceptable * Karnofsky performance status of \>= 70 * Hemoglobin \>= 10 g/dL * Total bilirubin =\< 2 mg/dL * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal (ULN) * Albumin \> 3.5 g/dL * Estimated glomerular filtration rate (eGFR) \>= 30 mL/min/1.73 m\^2 or creatinine clearance \>= 30 mL/min by Cockcroft-Gault * Serum potassium within normal limits * Negative serum or urine pregnancy test at screening for women of childbearing potential * Highly effective contraception for female subjects throughout the study and for at least 5 days after the last dose of study therapy if the risk of conception exists * Recovery to baseline or =\< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy * Willing to maintain a diary of all opioids used during the trial for the treatment of pain * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and instituti…